MiNK Therapeutics, Inc. (INKT) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-05

MiNK Therapeutics, Inc. (INKT) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-05. 2 Form 8-K material event filings were reported by INKT in the last 90 days. InsiderAlpha tracks every INKT SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About MiNK Therapeutics, Inc. (INKT)

SIC classification	Biological Products, (No Diagnostic Substances) (SIC 2836)
SEC CIK	0001840229

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-06-05

Recent INKT Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-04	Ryan Barbara	Insider	S — Open-market sale	1.0K	$12.80	$13K	SEC
2026-06-04	Ryan Barbara	Insider	S — Open-market sale	500	$12.68	$6K	SEC
2026-06-01	Ryan Barbara	Insider	A — Grant or award	1.4K	$12.38	$18K	SEC
2026-06-01	Behner Peter	Insider	A — Grant or award	1.3K	$12.38	$16K	SEC
2026-06-01	WIINBERG ULF	Insider	A — Grant or award	1.1K	$12.38	$14K	SEC
2026-06-01	Corvese Brian	Insider	A — Grant or award	1.4K	$12.38	$18K	SEC
2026-06-01	Holcomb John Bradley	Insider	A — Grant or award	1.1K	$12.38	$14K	SEC
2026-03-10	Ryan Barbara	Insider	S — Open-market sale	500	$15.57	$8K	SEC
2026-03-10	Ryan Barbara	Insider	S — Open-market sale	500	$15.30	$8K	SEC
2026-03-10	Ryan Barbara	Insider	S — Open-market sale	300	$15.28	$5K	SEC
2026-03-09	Ryan Barbara	Insider	S — Open-market sale	200	$10.17	$2K	SEC
2026-03-02	Corvese Brian	Insider	A — Grant or award	1.6K	$10.90	$18K	SEC
2026-03-02	Holcomb John Bradley	Insider	A — Grant or award	1.2K	$10.90	$14K	SEC
2026-03-02	Behner Peter	Insider	A — Grant or award	1.5K	$10.90	$16K	SEC
2026-03-02	Ryan Barbara	Insider	S — Open-market sale	100	$10.83	$1K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for MiNK Therapeutics, Inc. (INKT). Updated in real time as new filings are submitted to the SEC.

Most-Active INKT Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Ryan Barbara	4	$55K
WIINBERG ULF	2	$28K
Corvese Brian	2	$36K
Behner Peter	2	$33K
Holcomb John Bradley	2	$27K

Recent INKT Form 8-K Material Events

2026-06-23 — Item 5.07 [SEC]
2026-05-15 — Item 2.02, 9.01 [SEC]
2026-03-31 — Item 2.02, 9.01 · Earnings · neutral [SEC]
MiNK Therapeutics announced its financial results for Q4 2025 and full year 2025 on March 31, 2026. The filing provides standard quarterly and annual financial results without indication of beat/miss or guidance changes.
2026-03-27 — Item 8.01 · Clinical · positive [SEC]
MiNK Therapeutics clarified that it is actively engaged in discussions with multiple parties regarding potential combination trials involving agenT-797, its allogeneic iNKT cell therapy, as well as potential strategic minority investments. The company emphasized that these discus
2026-03-19 — Item 5.02 · Leadership · neutral [SEC]
MiNK Therapeutics appointed Melissa Orilall as Principal Financial Officer effective March 13, 2026. Orilall, age 37, is currently Vice President of Global Financial Operations at parent company Agenus and will provide services to MiNK through an intercompany services agreement w

Recent Insider Filings

2026-06-05 — Ryan Barbara (Insider)
2026-06-02 — Holcomb John Bradley (Insider)
2026-06-02 — Ryan Barbara (Insider)
2026-06-02 — Corvese Brian (Insider)
2026-06-02 — Behner Peter (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in INKT insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

INKT Insider Trading — FAQ

What is the latest insider trade for INKT?: MiNK Therapeutics, Inc. (INKT) had 6 insider filings in the last 90 days, with the most recent on 2026-06-05. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying INKT stock?: 0 insider purchases of INKT were filed in the last 90 days.
How many insiders are selling INKT stock?: 0 insider sales of INKT were filed in the last 90 days.
Where can I see INKT SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every INKT SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live INKT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.